Plain-English translation of NCT06946199 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called in people with rheumatoid arthritis (RA) that hasn't improved with current standard treatments. works by targeting immune cells that produce harmful antibodies responsible for RA. The study will follow participants for one year to see if the medication is safe and whether it helps reduce joint inflammation and pain.
Some people with RA don't get better even when taking the best available medications, leaving them with ongoing pain and disability. This medication uses a newer approach to fight the disease at a different level of the immune system, offering hope for patients who haven't benefited from existing treatments.
You likely qualify if…
You likely don't qualify if…
You would receive doses of the medication and come for regular study visits over 52 weeks (about one year) to monitor your health and how well the treatment works. The research team will check your blood work, assess your joint symptoms, and watch for any side effects. You'll be closely monitored to ensure the medication is safe and to track whether it helps improve your arthritis.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Enrollment target
~28 participants
Started
June 2025
Primary completion
June 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qiubai Li, Professor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.